Heart Failure Clinical Trials in Minneapolis, Minnesota
18 studies are recruiting for heart failure in Minneapolis, Minnesota right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
Alleviant ALLAY-HFrEF Study
Prospective, multicenter, randomized, sham-controlled, double blind (patient and observer), study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFrEF.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
- Locations
- 68 in total
- Run by
- Alleviant Medical, Inc.
-
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Participants include men and women ≥ 40 years of age with T2DM, established CV disease, a history of HTN with an SBP of at least 130 mmHg at screening, who meet the predefined serum potassium level, and with at least one additional risk factor for HF. The study will include an optional pre-screenin…
- Stage
- Phase 3
- Ages
- 40 and older
- Site
- Research Site, Minneapolis, Minnesota
- Locations
- 957 in total
- Run by
- AstraZeneca
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Minneapolis, MN Investigative Site 10091, Minneapolis, Minnesota
- Locations
- 356 in total
- Run by
- Colorado Prevention Center
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Combination therapy of finerenone plus empagliflozin will be compared to usual care to determine the efficacy and safety of treatment in patients hospitalized with heart failure.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Minneapolis, MN Investigative Site CON-10035, Minneapolis, Minnesota
- Locations
- 140 in total
- Run by
- Colorado Prevention Center
-
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
The goal of this study is to evaluate the safety and efficacy of the BrioVAD System by demonstrating non-inferiority to the HeartMate 3 Left Ventricular Assist System when used for the treatment of advanced, refractory, left ventricular heart failure.
- Stage
- Not phased
- Ages
- 18 to 100
- Site
- Abbott Northwestern Hospital, Minneapolis, Minnesota
- Locations
- 47 in total
- Run by
- BrioHealth Solutions, Inc.
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
This study is open to adults with chronic heart failure (HF) who have a reduced left ventricular ejection fraction (LVEF) of less than 40%. People can join the study if they have been diagnosed with chronic HF at least 3 months before they start on the study. The purpose of this study is to find ou…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Minneapolis VA Health Care System, Minneapolis, Minnesota
- Locations
- 588 in total
- Run by
- Boehringer Ingelheim
-
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK…
- Stage
- Not phased
- Ages
- 0 to 20
- Site
- University of Minnesota, Minneapolis, Minnesota
- Locations
- 52 in total
- Run by
- Duke University
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more. The purpose of this study is to find out whether vicadrostat (BI 690517) in combination with empa…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Minneapolis VA Health Care System, Minneapolis, Minnesota
- Locations
- 652 in total
- Run by
- Boehringer Ingelheim
-
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
- Stage
- Not phased
- Ages
- Any age
- Site
- Research site, Minneapolis, Minnesota
- Locations
- 333 in total
- Run by
- Medtronic
-
Alleviant ALLAY-HF Study
Prospective, multicenter, randomized, sham-controlled, double blinded, adaptive study designed to evaluate the safety and efficacy of a percutaneously created interatrial shunt using the Alleviant ALV1 System in patients with HFpEF/HFmrEF.
- Stage
- Not phased
- Ages
- 40 and older
- Site
- Minneapolis Heart Institute Foundation, Minneapolis, Minnesota
- Locations
- 93 in total
- Run by
- Alleviant Medical, Inc.
-
CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA)
The purpose of this multi-center clinical trial is to study the efficacy and safety of providing nutritional support added to the study-defined standard of care which consists of standardized dietary education and a single dietary counseling session shortly after discharge, versus study-defined sta…
- Stage
- Not phased
- Ages
- 60 and older
- Site
- Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
- Locations
- 16 in total
- Run by
- VA Office of Research and Development
-
Assessment of CCM in HF With Higher Ejection Fraction
The AIM HIGHer Clinical Trial will evaluate the safety and efficacy of Cardiac Contractility Modulation (CCM) therapy in patients with heart failure with LVEF ≥40% and ≤70%.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota
- Locations
- 105 in total
- Run by
- Impulse Dynamics
-
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by cha…
- Stage
- Phase 2
- Ages
- 40 to 84
- Site
- University of Minnesota_Minneapolis_1, Minneapolis, Minnesota
- Locations
- 117 in total
- Run by
- Novo Nordisk A/S
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients With Heart Failure Who Are Intolerant or Not Eligible for Treatment With Steroidal Mineralocorticoid Receptor Antagonists
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients with heart failure and reduced ejection fraction (HFrEF) who are intolerant or ineligible to receive treatment with steroidal mineralocorticoid receptor antagonists (sMRA).
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Minneapolis, MN Investigative Site FIN-10035, Minneapolis, Minnesota
- Locations
- 176 in total
- Run by
- Colorado Prevention Center
-
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
This is a prospective, multi-center, open label, randomized control clinical trial evaluating the safety and efficacy of the Cordella™ Pulmonary Artery Sensor System in NYHA Class II-III Heart Failure Patients (PROACTIVE-HF-2 Trial). The study contains of 5 arms: NYHA II Cohort - To demonstrate saf…
- Stage
- Not phased
- Ages
- 18 and older
- Site
- University of Minnesota, Minneapolis, Minnesota
- Locations
- 48 in total
- Run by
- Endotronix, Inc.
-
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Minneapolis Heart Institute, Minneapolis, Minnesota
- Locations
- 68 in total
- Run by
- Abbott Medical Devices
-
CCM OPEN HF Registry
The registry has been designed to evaluate the long-term safety and efficacy of CCM therapy in a real-world setting.
- Stage
- Not phased
- Ages
- 18 and older
- Site
- Minneapolis Heart Institute Research Foundation, Minneapolis, Minnesota
- Locations
- 28 in total
- Run by
- Impulse Dynamics
-
HF2 Registry - Hemodynamic Frontiers in Heart Failure Registry
The purpose of the HF2 (Hemodynamic Frontiers in Heart Failure) registry is to collect relevant patient-level demographic, clinical, laboratory, and hemodynamic data from patients implanted with pulmonary artery pressure sensor at participating centers to advance scientific knowledge about ambulato…
- Stage
- Not phased
- Ages
- 18 to 100
- Site
- Minneapolis Heart Institute Foundation/ Allina Health, Minneapolis, Minnesota
- Locations
- 12 in total
- Run by
- University of Kansas Medical Center
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.